`
`http://www. bausch. com/ om-company/investor-relations#. VkphGivz5Kj
`
`BAUSCH LOMB
`See better. Live better.
`
`.:i United States Newsroom Careers
`
`Investor Relations
`
`Contact Us
`
`For Eye Care
`Professionals
`
`Text size A- A+
`
`Our Products
`
`Vision and Age
`
`Your Eye Concerns
`
`Our Company
`
`Search ..
`
`Home > Our Company > Investor Relations
`
`Investor Relations
`
`Tweet 0
`L....i
`
`Like {I]
`Valeant Phannaceuticals International, Inc., (NYSE: VRX} (TSX: VRX) completed its acquisition of Bausch + Lomb on August
`5, 2013. Bausch+ Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses
`will be integrated into the Bausch+ Lomb division, creating a global eye health platfonn with estimated pro fonna 2013 net
`revenue of more than $3.5 billion. For Investor Relations infonnation on Valeant, click here.
`
`Vision and Eye Health
`
`Products
`
`Customer Support
`
`Legal
`
`Vision and Age
`Eye Infections & Irritations
`Diseases and Disorders
`Find a Doctor
`lilllJ=ye Exam Check Ust
`
`Contact Lenses
`Contact Lens Care
`Dry Eye Products
`Allergy/Redness Relief
`Rx Phannaceutical
`Eye Vitamins
`Surgical Products
`Vision Accessories
`
`Contact Us
`Customer policies and fonns
`Rebate Center
`Worldwide Locations
`
`Legal Notice
`Privacy Policy
`Safety Data Sheets (SDS)
`
`© 2015 Bausch & Lomb Incorporated.
`
`All infonnation and materials on this site pertain to the U.S. only, unless otherwise indicated.
`
`VA L EANT
`
`Newsroom
`Careers
`Investor Relations
`Grants & Contributions
`
`PAGE 1 OF 1
`
`1 of 1
`
`SENJU EXHIBIT 2184
`INNOPHARMA v SENJU
`IPR2015-00903
`11116/201 5 6:05PM